5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The uterine cancer therapeutics & diagnostics market is segmented by Type of Cancer (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma), Product, and Geography
Fastest Growing Market:
The Uterine Cancer Therapeutics & Diagnostics Market is expected to witness a growth of 6% CAGR owing to the growing awareness of uterine cancer and increasing healthcare expenditure. In the United States, the month of September is Gynecologic Cancer Awareness Month. The American Association for Cancer Research has stated in its article that endometrial carcinoma is common across the globe whereas, Uterine Sarcoma is considered as a rare type of cancer. CDC has stated that around 68% of the uterine cancers are the endometrial carcinomas.
Furthermore, developing countries like India has a National Cancer Control Programme which was established in 1975–76. This has contributed to the development of Regional Cancer Centres (RCCs), oncology wings in medical colleges and support for the purchase of teletherapy machines. In this country, the awareness programmes about the cancer are being conducted which is making the women aware of the severity of the disease.
Looking at the severity of the disease and importance of the women health, healthcare providers along with the governments are provoking awareness programmes in certain regions such as North America, Europe, and Asia-Pacific. With the growing focus of the government and the healthcare providers, it has been indicated that the market will grow rapidly in the over the forecast period.
As per the scope of the report, uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. The market is segmented by type of cancer, therapeutics, diagnostics and geography.
|By Cancer Type|
|Papillary Serous Carcinoma|
Report scope can be customized per your requirements. Click here.
Growing burden of endometrial adenocarcinoma is expected to drive the Uterine Cancer Therapeutics & Diagnostics Market in this segment. According to the Cancer.gov, an endometrial adenosarcoma is the most common type of cancer which is found in women and about 80 percent of uterine cancers are adenocarcinomas, and vary in degree of severity.
Increasing obesity among women is considered as the prime factor responsible for the growing incidence of the endometrium carcinoma as around 90% of the uterine cancers affect the endometrium. with the growing incidence of the disease and the rising awareness about the same, it is believed that rapid growth of the segment will occur in the coming future.
To understand key trends, Download Sample Report
North America region is believed to dominate the Global Uterine Cancer Therapeutics and Diagnostics Market in the near future. The prime reason for the growth of the market in this region is the rising incidence of the disease and the growing awareness among the general population. American Cancer Society estimates that in 2020, around 65,620 new cases of uterine body cancer in the United States. Furthermore, around 10% of uterine body cancers are sarcoma. In addition, rapid technological advancements in the diagnostics and faster adoption to new technologies in the country are provoking the overall growth of the market studied.
To understand geography trends, Download Sample Report.
The market studied is moderately competitive and most of the companies dealing with this market are the global players. However, with the rising technological advancements, smaller companies are also focusing on market penetration and are taking efforts to grab enough market share.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Awareness About Uterine Diseases and Their Available Therapies
4.2.2 Increasing Health Care Expenditure
4.2.3 Innovation in Drug Development and Subsequent Technological Advancements
4.3 Market Restraints
4.3.1 Low Success Rate in Clinical Trials for Cancer Drugs
4.3.2 High Cost Associated With the Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Cancer Type
5.1.1 Endometrial Adenocarcinoma
5.1.2 Adenosquamous Carcinoma
5.1.3 Papillary Serous Carcinoma
5.1.4 Uterine Sarcoma
5.2 By Product
126.96.36.199 Radiation Therapy
188.8.131.52 Pelvic Ultrasound
184.108.40.206 Dilation and Curettage
220.127.116.11 CT Scan
5.3.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
5.3.3 Asia Pacific
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.3.4 Middle East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East and Africa
5.3.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Ariad Pharmaceuticals, Inc.
6.1.2 Abbott Laboratories
6.1.3 Becton, Dickinson & Co.
6.1.4 GlaxoSmithKline Plc
6.1.5 Merck & Co., Inc.
6.1.6 Novartis AG
6.1.8 Siemens Healthcare Inc.
6.1.9 Roche Ltd
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments